Citations

Clear

12 citation(s) found for "Schnitzler, L".

Gender differences in use of prescription narcotic medications among living kidney donors
Lentine, Krista L. , Lam, Ngan N. , Schnitzler, Mark A. , Garg, Amit X. , Xiao, Huiling , Leander, Sheila, Brennan, Daniel C. , Taler, Sandra J. , Axelrod, David A. , Segev, Dorry L. , Segev, Dorry L , Axelrod, David , Schnitzler, Mark

Mayo Clinic

Clinical Transplantation | July 31, 2015 | Volume: 29 | Issue: 10 | Pages: 927-937

10.1111/ctr.12599 | PMID 26227016 Get It

AbstractPrescription narcotic use among living kidney donors is not well described. Using a unique database that integrates national registry identifiers for living kidney donors (1987–2007) in the United States with billing claims from a private health insurer (2000–2007), we identified pharmacy fills for prescription narcotic medications in periods 1–4 and >4 yr post‐donation and estimated relative likelihoods of post‐donation narcotic use by Cox regression. We also compared narcotic fill rates and medication possession ratios (MPRs, defined as (days of medication supplied)/(days observed)), between donors and age‐ and sex‐matched non‐donors. Overall, rates of narcotic medication fills were 32.3 and 32.4 per 100 person‐years in periods 1–4 and >4 yr post‐donation. After age and race adjustment, women were approximately twice as likely as men to fill a narcotic prescription in years 1–4 (adjusted hazard ratio, aHR, 2.28; 95% confidence interval, CI, 1.86–2.79) and >4 yr (aHR 1.70; 95% CI 1.50–1.93). MPRs in donors were low (<2.5% days exposed), and lower than among age‐ and sex‐matched non‐donors. Prescription narcotic medication use is more common among women than men in the intermediate term after live kidney donation. Overall, total narcotic exposure is low, and lower than among non‐donors from the general population.
Schnitzler's syndrome: diagnosis, treatment, and follow‐up
Simon, Anna , Asli, Bouchra, Braun‐Falco, Markus, Koning, Heleen D. de, Fermand, Jean‐Paul , Grattan, C, Krause, Karoline , Lachmann, Helen J. , Lenormand, C. , Martínez-Taboada, V., Maurer, Marcus , Peters, Margot S. , Rizzi, Rita , Rongioletti, Franco , Ruzicka, Thomas , Schnitzler, L, Schubert, B , Sibilia, Jean , Lipsker, Dan , Krause, Karoline , Lachmann, Helen

Mayo Clinic

Allergy | March 12, 2013 | Volume: 68 | Issue: 5 | Pages: 562-568

10.1111/all.12129 | PMID 23480774 Get It

AbstractSchnitzler's syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long‐term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler's syndrome be suspected? How should the diagnosis of Schnitzler's syndrome be established? How should a patient with Schnitzler's syndrome be treated? How should a patient with Schnitzler's syndrome be followed up?. A diagnosis of Schnitzler's syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First‐line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow‐up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.